ClinicalTrials.gg
Active, not recruitingNCT06564844TROPION-Lung12Updated Sep 23, 2026

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

A Phase 3 interventional study of Datopotamab Deruxtecan and Rilvegostomig in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 90 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
20th of 21
25 · median 278
Started
2024
with 3 others
Phase 3
9 of 21
3 open now
Primary completion
2026-07
later than 5 of 18 live
Registered
16th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by enrollment, is one of 4 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 5 of the 18 other live ones, and was the 16th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

Read the detailed description

The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Non-small Cell Lung Cancer
  • NSCLC
  • Adenocarcinoma
  • Stage I
  • Datopotamab Deruxtecan
  • Dato-DXd
  • Adjuvant Treatment
  • Rilvegostomig
  • Standard of Care
  • Pemetrexed
  • Carboplatin
  • Cisplatin
  • Vinorelbine
  • Etoposide
  • UFT
  • ctDNA-positive
  • High-risk Pathological Features
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. documented treatment-naive Stage I (T \< 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
  2. Complete surgical resection (R0) of the primary NSCLC
  3. Unequivocal no evidence of disease at post-surgical
  4. Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
  5. of 0 or 1, of > 6 months and complete recovery after surgery
  6. Adequate bone marrow reserve and organ function

Exclusion criteria

Exclusion Criteria:

  1. Sensitizing EGFR mutation and/or ALK alteration
  2. History of non-infectious ILD/pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  3. Significant pulmonary function compromise
  4. History of another primary within 3 years (with exceptions)
  5. Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
  6. Active or prior documented or inflammatory disorders (with exceptions)
  7. Active infection with tuberculosis, or C virus, hepatitis A, or known infection that is not well controlled
  8. History of active primary immunodeficiency
  9. corneal disease
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Dato-DXd + rilvegostomig

    Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).

    Drug: Datopotamab Deruxtecan · Drug: Rilvegostomig

  • Experimental
    Rilvegostomig

    Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).

    Drug: Rilvegostomig

  • Active comparator
    Standard of Care (SoC)

    Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC).

    Drug: Carboplatin · Drug: Cisplatin · Drug: Etoposide · Drug: Pemetrexed · Drug: Vinorelbine · Drug: UFT

Interventions

  • Datopotamab Deruxtecan IV (intravenous)

    Also known as: Dato-DXd, DS-1062a

  • Rilvegostomig IV (intravenous)

    Also known as: AZD2936

  • Carboplatin IV (intravenous), Active Comparator

  • Cisplatin IV (intravenous), Active Comparator

  • Etoposide IV (intravenous), Active Comparator

  • Pemetrexed IV (intravenous), Active Comparator

  • Vinorelbine IV (intravenous), Active Comparator

  • DrugUFT

    UFT Oral route of administration, Active Comparator

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC

    The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

    Time frame: From date of randomisation up to approximately 10 years.

Secondary outcomes

  1. Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC

    The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

    Time frame: From date of randomisation up to approximately 10 years.

  2. Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC

    The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

    Time frame: Measured at weeks 12, 24 and 48.

  3. Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC

    The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

    Time frame: Measured at weeks 12, 24 and 48.

  4. Pharmacokinetics (PK)

    Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum.

    Time frame: Up to 30 or 90 days post-last dose of study intervention.

  5. Pharmacokinetics (PK)

    Concentration of rilvegostomig in plasma or serum.

    Time frame: Up to 30 or 90 days post-last dose of study intervention.

  6. Pharmacokinetics (PK)

    PK parameters (peak and through concentrations).

    Time frame: Up to 30 or 90 days post-last dose of study intervention.

  7. Immunogenicity

    Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples).

    Time frame: Up to 30 or 90 days post-last dose of study intervention.

07

Study locations

90 sites
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Lone Tree, Colorado 80124, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    St. Petersburg, Florida 33709, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Evanston, Illinois 60201, United States
  • Research Site
    Zion, Illinois 60099, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Baltimore, Maryland 21237, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Billings, Montana 59102, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Barretos, 14784-057, Brazil
  • Research Site
    Brasília, 70200-730, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    Teresina, 64049-200, Brazil
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Montreal, Quebec H2X 3J4, Canada
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Chiba, 260-0877, Japan
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Hidaka-shi, 350-1298, Japan
  • Research Site
    Hiroshima, 730-8518, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Iwakuni-shi, 740-8510, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kobe, 650-0017, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Nagoya, 464-8681, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Osakasayama-shi, 589-8511, Japan
  • Research Site
    Sapporo, 003-0804, Japan
  • Research Site
    Sendai, 980-0873, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Wakayama, 641-8510, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Kuala Lumpur, 50586, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Bangkoknoi, 10700, Thailand
  • Research Site
    Banphaeo, 74120, Thailand
  • Research Site
    Dusit, 10300, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Muang, 40002, Thailand
  • Research Site
    Muang, 50200, Thailand
  • Research Site
    Ratchathewi, 10400, Thailand
  • Research Site
    Ankara, 06010, Turkey (Türkiye)
  • Research Site
    Ankara, 06280, Turkey (Türkiye)
  • Research Site
    Mersin, 33240, Turkey (Türkiye)
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hà Nội, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Vinh, 460000, Vietnam
08

References and documents

Publications

  • Jones DR, Opitz I, Harpole D, Yanagawa J, Lim E, Tsutani Y, Tan DSW, Dacic S, Ganti AK, Bodla S, Batig A, Lyfar P, Forcina A, Felip E. TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026 Jan;171(1):1-9. doi: 10.1016/j.jtcvs.2025.09.017. Epub 2025 Sep 19. PubMed 40976544 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2026, 20 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 20 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 21, 2024
StartActual
Oct 15, 2024
Primary completionActual
Jul 10, 2026
CompletionEst.
Mar 31, 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564844
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Oct 15, 2024
Primary completion
Jul 10, 2026
Completion
Mar 31, 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

David Jones, MD
principal investigator · Memorial Sloan Kettering Cancer Center, New York, United States of America
Enriqueta Felip, MD
principal investigator · Vall d'Hebron Hospital, Barcelona, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Rilvegostomig

Start the discussion